Interview: John Markels – Managing Director, MSD Mexico
The managing director of MSD in Mexico explains why the Mexican pharmaceutical market is an attractive market in which to compete, but not one that will deliver 12 to 15…
MSD in Mexico is the local subsidiary of Merck & Co., Inc., a leading research-driven pharmaceutical company that discovers, develops, manufactures and markets a broad range of innovative health care products. As the leading research-based pharmaceutical company inMexico, MSD is committed to maintaining and improving the quality of human life above all else.
Contact Details
Avenida San Jeronimo No.369, Tizapan San Angel, Mexico DF, Mexico
Tel: +52 55 5481 9600
Web: http://www.corporativo.msd.com.mx/
The managing director of MSD in Mexico explains why the Mexican pharmaceutical market is an attractive market in which to compete, but not one that will deliver 12 to 15…
We read in an article by El Economista last year that you believe “there is no other company with such a diverse range of therapies as MSD and that makes…
Chiesi Mexico’s Marco Ruggiero discusses his initial impressions of the Mexican pharma market, his strategic priorities for the affiliate, and the increasing importance of the company’s respiratory portfolio in Mexico.…
Novartis Mexico Country President Fernando Cruz outlines the new normal for Mexican healthcare post-regulatory reform, how the company’s global reshuffle has impacted Mexican operations, and the challenges inherent in bringing…
David López García, Mexico country manager of global rare genetic therapy player Biomarin, outlines the challenging situation around patient access to orphan drugs in Mexico and the importance of building…
Dr David Kershenobich Stalnikowitz, director-general of the Salvador Zubirán National Institute of Medical Sciences and Nutrition (INCMNSZ) shares the many new initiatives the Institute has introduced in the past couple…
In the historic year of their 70th anniversary, Cristóbal Thompson, executive director of the Asociación Mexicana de Industrias de Investigación Farmacéutica (AMIIF), the association for research-based pharmaceutical companies in Mexico,…
Rafael Gual Cosío, director general of the Cámara Nacional de la Industria Farmacéutica (CANIFARMA), the umbrella industry association for the healthcare sector in Mexico, shares his perspectives on the complex…
The election of populist President Andres Manuel Lopez Obrador (AMLO) on 1 July 2018 heralded a new era of hope and optimism for Mexicans. In the first 13 months of…
Juan de Villafranca, executive director of the Asociacion Mexicana de Laboratorios Farmaceuticos (AMELAF), shares the exciting new initiatives he has launched in the past two years of his term; the…
Below is a selection of top recent news from Mexican pharma and healthcare, including the healthcare reforms president Andres Manuel Lopez Obrador is prioritising, latest news on the INSABI program,…
Between 2015 and 2017 PharmaBoardroom met with pharma country managers in Mexico who spoke about the challenges and opportunities present in the Mexican market. Since then, these five stakeholders have…
The United States Trade Representative Office has been engaging with a number of countries, including Mexico, to address concerns related to IP protection and enforcement and market access barriers for…
What traits, competencies and drivers do you need to be a successful pharma country manager in today’s dynamic Mexican pharma market? Jose Guerrero and Male Mejido from the Mexico office…
See our Cookie Privacy Policy Here